AI Article Synopsis
Article Abstract
With 4 mg folic acid daily, it may take 20 weeks to reach red-blood-cell folate levels between 1050 and 1340 nmol/L, optimal for reduction of the neural tube defect risk. Therefore, folic acid supplementation should be started 5-6 months before conception. The residual risk with optimal red-blood-cell folate levels is reportedly 4.5 per 10,000 total births. The residual risk in pooled data from countries with mandatory folic acid fortification is 7.5 per 10,000 pregnancies, regardless of pre-fortification rates. European monitoring of folate intake with questionnaires should be replaced by periodic measurements of red-blood-cell folate. The risk of folate intake >1 mg/day does not outweigh the benefits of folic acid fortification, provided un-metabolized folic acid, RBC folate and vitamin B are monitored periodically. A European monitoring system, based on U.S. National Health and Nutrition Examination Surveys, should reside with the European Centre for Disease Prevention and Control.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.reprotox.2018.05.004 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Improvement in biochemical manifestations of the serum and follicular fluid and ICSI outcomes in PCOS patients with myo-inositol administration: prospective randomized research.
Naunyn Schmiedebergs Arch Pharmacol
December 2024
Department of Biology, Parand Branch, Islamic Azad University, Bahonar Blvd, Tehran, Iran.
The research investigated the capacity of myo-inositol (MI) in order that it improves biochemical markers in serum and follicular fluid and, ultimately, intracytoplasmic sperm injection (ICSI) outcomes of women with PCOS. Sixty infertile patients with PCOS, who were undergoing ovulation induction for ICSI, were randomly divided to two groups. The MI group received 2000 mg myo-inositol + 1 mg folic acid twice a day for 6 weeks with starting the ICSI cycle.
View Article and Find Full Text PDFEffectiveness of Health Education Interventions in Enhancing Iron-Folic Acid Supplement Utilization Among Pregnant Women: Systematic Review and Meta-analysis.
Nutr Rev
December 2024
Department of Applied Social Sciences, Faculty of Health and Social Sciences, The Hong Kong Polytechnic University, Hong Kong, People's Republic of China.
Context: During pregnancy, the underutilization of iron-folic acid supplements (IFAS) remains a considerable maternal and child health issue. Hence, health education intervention trials were conducted following the recommendation of the World Health Organization and epidemiological studies to enhance the utilization level of the supplements during pregnancy.
Objective: The objective of this meta-analysis was to evaluate the effectiveness of health education interventions in enhancing IFAS utilization during pregnancy.
Second-line systemic treatment for metastatic colorectal cancer: A systematic review and Bayesian network meta-analysis based on RCT.
PLoS One
December 2024
Department of Colorectal Surgery, The Affiliated Xuzhou Clinical College of Xuzhou Medical University, Xuzhou Central Hospital, Xuzhou, Jiangsu, China.
Background: The optimal second-line systemic treatment for metastatic colorectal cancer (mCRC) is inconclusive.
Methods: We searched PubMed, Web of Science, EMBASE, and Cochrane Library for RCTs comparing second-line systemic treatments for mCRC from the inception of each database up to February 3, 2024. Markov Chain Monte Carlo (MCMC) technique was used in this network meta-analysis (NMA) to generate the direct and indirect comparison results among multiple treatments in progression-free survival (PFS), overall response rate (ORR), overall survival (OS), complete response (CR), partial response (PR), grade 3 and above adverse events (Grade ≥ 3AE), and any adverse events (Any AE).
Global research progress of nanomedicine and colorectal cancer: a bibliometrics and visualization analysis.
Front Oncol
December 2024
Proctology Department, Affiliated Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China.
Background: Surgery and chemoradiotherapy are the main clinical treatment methods for colorectal cancer (CRC), but the prognosis is poor. The emergence of nanomedicine brings bright light to the treatment of CRC. However, there has not been a comprehensive and systematic analysis of CRC and nanomedicine by bibliometrics.
View Article and Find Full Text PDF5-Methyltetrahydrofolate and aqueous extract of () ameliorate diabetes and associated complications in STZ-induced diabetic rats.
3 Biotech
January 2025
Plant Cell Biotechnology (PCBT) Department, Central Food Technological Research Institute (CFTRI), Mysuru, 570 020 India.
Unlabelled: The present study evaluated the effects of 5-methyltetrahydrofolate (5-MTHF) and aqueous extract on diabetes. An in silico docking study with select bioactive compounds showed strong binding affinities of folates with glucose metabolism-related proteins. In vitro assay showed 5-MTHF's superior inhibitory activity on alpha-amylase compared to folic acid.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!